S100A9 and Sepsis: Here, our study further demonstrated that the pharmacological inhibition of S100A9 with Paq effectively improved sepsis-induced liver injury and mitochondrial dysfunction in CLP-treated mice (Figure 6 and Figure 7), suggesting that blocking S100A9 may be a new therapeutic approach for sepsis-induced liver injury.